Intestinal incretins and the regulation of bone physiology

Walter Ramsey, Carlos M Isales

Research output: Chapter in Book/Report/Conference proceedingChapter

10 Citations (Scopus)

Abstract

Although originally identified as modulators of nutrient absorption, the gut hormones gastric inhibitory polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon-like peptide-2 (GLP-2) have also been found to play an important role in the regulation of bone turnover. These “incretin” hormones promote bone anabolism by stimulating osteoblast differentiation as well as increasing osteoblast longevity. In addition, GIP and perhaps GLP-2 attenuate the activity of osteoclastic cells, leading to a net increase in bone deposition and ultimately increasing bone mass. Studies have demonstrated that these hormones are important for bone mineralization and overall bone quality and function evolutionarily as important nutritional links signaling nutrient availability for skeletal anabolic functions. Accordingly, these entero-osseous hormones (EOH) have therapeutic potential for the management of osteoporosis. Although this chapter primarily focuses on skeletal effects of these incretin hormones, the GIP, GLP-1, and GLP-2 receptors are actually widely expressed throughout the body. Therefore, we will also briefly discuss these extraosseous receptors/effects and how they may indirectly impact the skeleton.

Original languageEnglish (US)
Title of host publicationAdvances in Experimental Medicine and Biology
PublisherSpringer New York LLC
Pages13-33
Number of pages21
DOIs
StatePublished - Jan 1 2017

Publication series

NameAdvances in Experimental Medicine and Biology
Volume1033
ISSN (Print)0065-2598
ISSN (Electronic)2214-8019

Fingerprint

Incretins
Physiology
Gastric Inhibitory Polypeptide
Bone
Hormones
Bone and Bones
Glucagon-Like Peptide 2
Glucagon-Like Peptide 1
Osteoblasts
Nutrients
Food
Physiologic Calcification
Bone Remodeling
Skeleton
Osteoporosis
Modulators
Cells
Availability

Keywords

  • Bone turnover
  • Entero-osseous hormone(s)
  • GIP
  • GLP-1
  • GLP-2
  • Gut-bone (entero-osseous) signaling axis

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Ramsey, W., & Isales, C. M. (2017). Intestinal incretins and the regulation of bone physiology. In Advances in Experimental Medicine and Biology (pp. 13-33). (Advances in Experimental Medicine and Biology; Vol. 1033). Springer New York LLC. https://doi.org/10.1007/978-3-319-66653-2_2

Intestinal incretins and the regulation of bone physiology. / Ramsey, Walter; Isales, Carlos M.

Advances in Experimental Medicine and Biology. Springer New York LLC, 2017. p. 13-33 (Advances in Experimental Medicine and Biology; Vol. 1033).

Research output: Chapter in Book/Report/Conference proceedingChapter

Ramsey, W & Isales, CM 2017, Intestinal incretins and the regulation of bone physiology. in Advances in Experimental Medicine and Biology. Advances in Experimental Medicine and Biology, vol. 1033, Springer New York LLC, pp. 13-33. https://doi.org/10.1007/978-3-319-66653-2_2
Ramsey W, Isales CM. Intestinal incretins and the regulation of bone physiology. In Advances in Experimental Medicine and Biology. Springer New York LLC. 2017. p. 13-33. (Advances in Experimental Medicine and Biology). https://doi.org/10.1007/978-3-319-66653-2_2
Ramsey, Walter ; Isales, Carlos M. / Intestinal incretins and the regulation of bone physiology. Advances in Experimental Medicine and Biology. Springer New York LLC, 2017. pp. 13-33 (Advances in Experimental Medicine and Biology).
@inbook{08c241fa248e481fac54a0a7e0f46fd3,
title = "Intestinal incretins and the regulation of bone physiology",
abstract = "Although originally identified as modulators of nutrient absorption, the gut hormones gastric inhibitory polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon-like peptide-2 (GLP-2) have also been found to play an important role in the regulation of bone turnover. These “incretin” hormones promote bone anabolism by stimulating osteoblast differentiation as well as increasing osteoblast longevity. In addition, GIP and perhaps GLP-2 attenuate the activity of osteoclastic cells, leading to a net increase in bone deposition and ultimately increasing bone mass. Studies have demonstrated that these hormones are important for bone mineralization and overall bone quality and function evolutionarily as important nutritional links signaling nutrient availability for skeletal anabolic functions. Accordingly, these entero-osseous hormones (EOH) have therapeutic potential for the management of osteoporosis. Although this chapter primarily focuses on skeletal effects of these incretin hormones, the GIP, GLP-1, and GLP-2 receptors are actually widely expressed throughout the body. Therefore, we will also briefly discuss these extraosseous receptors/effects and how they may indirectly impact the skeleton.",
keywords = "Bone turnover, Entero-osseous hormone(s), GIP, GLP-1, GLP-2, Gut-bone (entero-osseous) signaling axis",
author = "Walter Ramsey and Isales, {Carlos M}",
year = "2017",
month = "1",
day = "1",
doi = "10.1007/978-3-319-66653-2_2",
language = "English (US)",
series = "Advances in Experimental Medicine and Biology",
publisher = "Springer New York LLC",
pages = "13--33",
booktitle = "Advances in Experimental Medicine and Biology",

}

TY - CHAP

T1 - Intestinal incretins and the regulation of bone physiology

AU - Ramsey, Walter

AU - Isales, Carlos M

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Although originally identified as modulators of nutrient absorption, the gut hormones gastric inhibitory polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon-like peptide-2 (GLP-2) have also been found to play an important role in the regulation of bone turnover. These “incretin” hormones promote bone anabolism by stimulating osteoblast differentiation as well as increasing osteoblast longevity. In addition, GIP and perhaps GLP-2 attenuate the activity of osteoclastic cells, leading to a net increase in bone deposition and ultimately increasing bone mass. Studies have demonstrated that these hormones are important for bone mineralization and overall bone quality and function evolutionarily as important nutritional links signaling nutrient availability for skeletal anabolic functions. Accordingly, these entero-osseous hormones (EOH) have therapeutic potential for the management of osteoporosis. Although this chapter primarily focuses on skeletal effects of these incretin hormones, the GIP, GLP-1, and GLP-2 receptors are actually widely expressed throughout the body. Therefore, we will also briefly discuss these extraosseous receptors/effects and how they may indirectly impact the skeleton.

AB - Although originally identified as modulators of nutrient absorption, the gut hormones gastric inhibitory polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon-like peptide-2 (GLP-2) have also been found to play an important role in the regulation of bone turnover. These “incretin” hormones promote bone anabolism by stimulating osteoblast differentiation as well as increasing osteoblast longevity. In addition, GIP and perhaps GLP-2 attenuate the activity of osteoclastic cells, leading to a net increase in bone deposition and ultimately increasing bone mass. Studies have demonstrated that these hormones are important for bone mineralization and overall bone quality and function evolutionarily as important nutritional links signaling nutrient availability for skeletal anabolic functions. Accordingly, these entero-osseous hormones (EOH) have therapeutic potential for the management of osteoporosis. Although this chapter primarily focuses on skeletal effects of these incretin hormones, the GIP, GLP-1, and GLP-2 receptors are actually widely expressed throughout the body. Therefore, we will also briefly discuss these extraosseous receptors/effects and how they may indirectly impact the skeleton.

KW - Bone turnover

KW - Entero-osseous hormone(s)

KW - GIP

KW - GLP-1

KW - GLP-2

KW - Gut-bone (entero-osseous) signaling axis

UR - http://www.scopus.com/inward/record.url?scp=85033226277&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85033226277&partnerID=8YFLogxK

U2 - 10.1007/978-3-319-66653-2_2

DO - 10.1007/978-3-319-66653-2_2

M3 - Chapter

C2 - 29101649

AN - SCOPUS:85033226277

T3 - Advances in Experimental Medicine and Biology

SP - 13

EP - 33

BT - Advances in Experimental Medicine and Biology

PB - Springer New York LLC

ER -